Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$260.23 USD

260.23
1,560,182

+5.76 (2.26%)

Updated Aug 25, 2026 04:00 PM ET

After-Market: $260.28 +0.05 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

by Zacks Equity Research

Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

    Zacks Equity Research

    5 Stocks Near 52-Week High With More Room to Run

    by Zacks Equity Research

    Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.

      Zacks Equity Research

      5 Best Bargain PEG Stocks That Value Investors Love

      by Zacks Equity Research

      While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.

        Zacks Equity Research

        Jazz Pharmaceuticals (JAZZ) Up 16.9% Since Earnings Report: Can It Continue?

        by Zacks Equity Research

        Jazz Pharmaceuticals (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

          Zacks Equity Research

          Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates

          by Zacks Equity Research

          Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q1 and also raises the lower end of its earnings and sales guidance for 2018.

            Zacks Equity Research

            Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?

            by Zacks Equity Research

            Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.

              Zacks Equity Research

              Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?

              by Zacks Equity Research

              Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.

                Zacks Equity Research

                Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y

                by Zacks Equity Research

                Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.

                  Zacks Equity Research

                  Jazz Pharmaceuticals (JAZZ) Q4 Earnings: What to Expect?

                  by Zacks Equity Research

                  In Q4, we expect investors' focus on Xyrem's performance, Jazz Pharmaceuticals' (JAZZ) lead product for excessive daytime sleepiness. Also, hopes will be pinned on the company's pipeline progress.

                    Zacks Equity Research

                    Concert Pharmaceuticals Plunges on Patent Petition Setback

                    by Zacks Equity Research

                    Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.